Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine

Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years

(2016) Hung Fu Tseng et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

(2016) Anthony L. Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults

(2016) Roman Chlibek et al.   VACCINE

Annual incidence rates of herpes zoster among an immunocompetent population in the United States

(2015) Barbara H. Johnson et al.   BMC INFECTIOUS DISEASES

Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries

(2015) Oliver Damm et al.   BMC PUBLIC HEALTH

Predictors of postherpetic neuralgia in patients with herpes zoster: a pooled analysis of prospective cohort studies from North and Latin America and Asia

(2015) Kosuke Kawai et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults

(2015) Myron J. Levin et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

(2015) Himal Lal et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients

(2014) E. A. Stadtmauer et al.   BLOOD

Long-term Persistence of Zoster Vaccine Efficacy

(2014) Vicki A. Morrison et al.   CLINICAL INFECTIOUS DISEASES

Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells

(2014) Arnaud M. Didierlaurent et al.   JOURNAL OF IMMUNOLOGY

Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study

(2014) Roman Chlibek et al.   VACCINE

Systematic review of incidence and complications of herpes zoster: towards a global perspective

(2014) K. Kawai et al.   BMJ Open

Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of Age

(2013) R. Chlibek et al.   JOURNAL OF INFECTIOUS DISEASES

Herpes Zoster

(2013) Jeffrey I. Cohen   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su)

(2013) Himal Lal et al.   Human Vaccines & Immunotherapeutics

Persistence of the Efficacy of Zoster Vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy

(2012) K. E. Schmader et al.   CLINICAL INFECTIOUS DISEASES

Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years

(2012) K. E. Schmader et al.   CLINICAL INFECTIOUS DISEASES

A Phase 1/2 Clinical Trial Evaluating Safety and Immunogenicity of a Varicella Zoster Glycoprotein E Subunit Vaccine Candidate in Young and Older Adults

(2012) Isabel Leroux-Roels et al.   JOURNAL OF INFECTIOUS DISEASES

Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems

(2011) Nathalie Garçon et al.   Expert Review of Vaccines

Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors

(2010) G. N. Malavige et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Advances in the understanding of the pathogenesis and epidemiology of herpes zoster

(2010) Anne A. Gershon et al.   JOURNAL OF CLINICAL VIROLOGY

Varicella‐Zoster Virus–Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine

(2009) Adriana Weinberg et al.   JOURNAL OF INFECTIOUS DISEASES